Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Traws Pharma, Inc. - Common Stock (NQ: TRAW )

4.865 +0.165 (+3.51%)
Streaming Delayed Price Updated: 3:54 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,232
Open 4.680
Bid (Size) 4.730 (3)
Ask (Size) 4.900 (2)
Prev. Close 4.700
Today's Range 4.680 - 4.930
52wk Range 4.440 - 24.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
From Traws Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
-77.29%
-77.29%
1 Month
-36.78%
-36.78%
3 Month
-54.91%
-54.91%
6 Month
-70.96%
-70.96%
1 Year
-77.29%
-77.29%

More News

Read More
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
From Traws Pharma, Inc.
Via GlobeNewswire
TRAW Stock Earnings: Traws Pharma Reported Results for Q2 2024
Via InvestorPlace
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
From Traws Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
From Traws Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For April 16, 2024
Via Benzinga
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.